Christine M. Cotter

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

Elizabeth C. Randall, E. Winer, N. Ibrahim, 2020, Clinical breast cancer.

Translational Breast Cancer Research Consortium 022: Pre- and Post-operative Neratinib for HER2-positive Breast Cancer Brain Metastases

Elizabeth C. Randall, E. Winer, N. Ibrahim, 2020 .

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

E. Winer, N. Ibrahim, R. Gelman, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).

E. Winer, Minetta C. Liu, R. Gelman, 2017 .

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

Yulei N. Wang, R. Finn, Chih-Hung Hsu, 2023, Journal of Clinical Oncology.

First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.

D. Xuan, H. Burris, D. Hong, 2015 .

Translational Breast Cancer Research Consortium 022: Pre- and Post-operative Neratinib for HER2-positive Breast Cancer Brain Metastases

Elizabeth C. Randall, E. Winer, N. Ibrahim, 2020 .